Please note, this OEL/ADE monograph also applies to dibucaine hydrochloride (CAS RN 61-12-1). Dibucaine is indicated for use as a local anesthesia, to relieve pain, itching, and inflammation associated with minor skin disorders. Dibucaine shares the pharmacologic effects of other local anesthetics, and acts by blocking nerve conduction first in the autonomic, then in sensory, and finally motor nerve fibers. Nerve conduction appears to be blocked by dibucaine as a result of a decrease in the permeability of the nerve cell membrane to sodium ions. Competition with calcium ions for membrane binding sites also appears to be involved. Local anesthetics may also reduce the permeability of resting nerves to potassium, as well as to sodium ions.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Dibucaine, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.